8.26.02: Specialty Pharmaceuticals Issue
Six Analysts and top management from seventeen sector firms examine the Specialty Pharmaceuticals sector in this 95 - page Special Focus - Specialty Pharmaceuticals Issue from The Wall Street Transcript.
    Online subscribers to the Healthcare sector also get
    Medical Technology/Orthopedics Issue &
    Biotechnology Issue
  1. Specialty Pharmaceuticals - In an in-depth (11,600) words) Analyst Roundtable, Dr. Steven B. Gerber, CIBC World Markets, Marc Goodman, Morgan Stanley, Maria Legatos-Phillips, Banc of America Securities, Erick Lucera, Independence Investment LLC, David Steinberg, Deutsche Bank Securities, examine the outlook for the sector and share specific stock recommendations.
  2. Pharmaceuticals - In an in-depth (2,900 words) Analyst Interview, Rodney C. Singleton, G.W. Henssler & Associates, Ltd., examines the outlook for the sector and share specific stock recommendations.
  3. CEO interviews (average 2,500 words). Top management of 17 - sector firms examine the outlook for their firm and the sector. Firms include:
    Sharp Compliance, Discovery Laboratories, Forbes Medi-Tech, GeneMax Corp, Genetronics, International Isotopes, King Pharmaceuticals, Lorus Therapeutics, MGI PHARMA, Mylan Laboratories, Orphan Medical, Polydex Pharmaceuticals, POZEN, Questcor Pharmaceuticals, Shire Pharmaceuticals, Ventiv Health, Zila, Inc.
    4. ORDER THIS REPORT NOW! ONLY $175
    The report will be mailed first class. For fedex delivery, specify in the report details section and either include your fedex number or we will add $15 delivery charge. All sales are final.  Questions, call (212) 952-7433, or email us
    For immediate access online - click here to gain a password.
     
    Report details:  
    Your Name:  
    		 Company: 
    Address: 
    		 City: 
    State/Province:
    		 ZIP/Postal Code:
          		 Country:
    Phone:
    		 E-Mail:

    BILLING INFORMATION
    Credit Card
    		 Expiration Month/Year:
    Credit Card Number: 
     

     This Issue costs $175 - and is non-returnable.   

    The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.

     

Investors and Industry Execs.

The Wall Street Transcript has been used by investors and industry executives for 40 years as a unique tool for company and industry research.

TWST's roundtable panels and analyst interviews provide a sector perspective from Wall Street's best. 

Money manager interviews provide the view from the buy-side.

CEO interviews with hundreds of companies from the major sectors gives the company perspective right from the top.

Subscribe to a unique research tool for investors and industry executives. Call (212) 952 7433 or click here.

Sincerely,

Andrew Pickup
Publisher
HOME PRODUCTS SUBSCRIBE ABOUT ARCHIVE HOTLINE CONTACT EUROPE